289
Participants
Start Date
August 31, 2008
Primary Completion Date
November 30, 2012
Study Completion Date
December 31, 2012
Paclitaxel
175 mg/m2, 1-3 hour IV infusion Day 1
Carboplatin
AUC 6.0 IV Day 1
Bevacizumab
15 mg/kg IV infusion Day 1
Erlotinib
150 mg PO
Treatment determined by physician
Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
Spartanburg Regional Medical Center, Spartanburg
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Integrated Community Oncology Network, Jacksonville
Florida Hospital Cancer Institute, Orlando
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Oncology Specialties (Clearview Cancer Institute), Huntsville
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Jackson Oncology Associates, Jackson
Baptist Hospital East, Louisville
Oncology Hematology Care, Cincinnati
Oncology Hematology Associates of SW Indiana, Evansville
Grand Rapids Clinical Oncology Program, Grand Rapids
Nebraska Methodist Cancer Center, Omaha
Hematology Oncology Clinic, LLP, Baton Rouge
Center for Cancer and Blood Disorders, Fort Worth
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Genentech, Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER